Thomas F. Gajewski to Neoplasms
This is a "connection" page, showing publications Thomas F. Gajewski has written about Neoplasms.
Connection Strength
8.322
-
Tissue-resident memory T cells in immune-related adverse events: friend or foe? Oncoimmunology. 2023; 12(1):2197358.
Score: 0.299
-
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. J Immunother Cancer. 2022 06; 10(6).
Score: 0.282
-
Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy. Gastroenterology. 2021 01; 160(2):600-613.
Score: 0.254
-
Strategies to overcome resistance to PD-1 inhibitors. Clin Adv Hematol Oncol. 2020 May; 18(5):270-272.
Score: 0.244
-
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-?-signaling mutant cancer cells. Nat Commun. 2020 01 30; 11(1):602.
Score: 0.240
-
PAK4 as a cancer immune-evasion target. Nat Cancer. 2020 01; 1(1):18-19.
Score: 0.238
-
STING pathway agonism as a cancer therapeutic. Immunol Rev. 2019 07; 290(1):24-38.
Score: 0.230
-
Exploring the emerging role of the microbiome in cancer immunotherapy. J Immunother Cancer. 2019 04 17; 7(1):108.
Score: 0.227
-
Back from the dead: TIL apoptosis in cancer immune evasion. Br J Cancer. 2018 02 06; 118(3):309-311.
Score: 0.208
-
Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer. 2018 03; 18(3):139-147.
Score: 0.208
-
Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity. Cancer Immunol Res. 2018 01; 6(1):14-24.
Score: 0.205
-
The Microbiota: A New Variable Impacting Cancer Treatment Outcomes. Clin Cancer Res. 2017 07 01; 23(13):3229-3231.
Score: 0.198
-
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. Clin Cancer Res. 2017 07 01; 23(13):3269-3276.
Score: 0.194
-
Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. Adv Exp Med Biol. 2017; 1036:19-31.
Score: 0.194
-
Innate immune signaling and regulation in cancer immunotherapy. Cell Res. 2017 Jan; 27(1):96-108.
Score: 0.193
-
The host STING pathway at the interface of cancer and immunity. J Clin Invest. 2016 07 01; 126(7):2404-11.
Score: 0.187
-
Manipulating the microbiome to improve the efficacy of immunotherapy. Clin Adv Hematol Oncol. 2016 Jun; 14(6):424-6.
Score: 0.186
-
Germ Warfare. Sci Am. 2016 Apr; 314(4):50.
Score: 0.184
-
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy. Adv Immunol. 2016; 130:75-93.
Score: 0.181
-
Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer. Clin Cancer Res. 2015 Nov 01; 21(21):4774-9.
Score: 0.177
-
Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy. Cytokine. 2016 Jan; 77:245-7.
Score: 0.176
-
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol. 2015 Aug; 42(4):663-71.
Score: 0.173
-
The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol. 2015 Apr; 36(4):250-6.
Score: 0.171
-
Innate immune recognition of cancer. Annu Rev Immunol. 2015; 33:445-74.
Score: 0.169
-
New perspectives on type I IFNs in cancer. Cytokine Growth Factor Rev. 2015 Apr; 26(2):175-8.
Score: 0.169
-
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013 Oct; 14(10):1014-22.
Score: 0.154
-
Cancer immunotherapy. Curr Opin Immunol. 2013 Apr; 25(2):259-60.
Score: 0.150
-
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol. 2013 Apr; 25(2):268-76.
Score: 0.149
-
Type I interferon response and innate immune sensing of cancer. Trends Immunol. 2013 Feb; 34(2):67-73.
Score: 0.145
-
Innate immune sensing of cancer: clues from an identified role for type I IFNs. Cancer Immunol Immunother. 2012 Aug; 61(8):1343-7.
Score: 0.141
-
Cancer immunotherapy. Mol Oncol. 2012 Apr; 6(2):242-50.
Score: 0.137
-
Harnessing the immune response. Clin Adv Hematol Oncol. 2012 Jan; 10(1):46-8.
Score: 0.137
-
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol. 2011 Apr; 23(2):286-92.
Score: 0.127
-
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs. 2010 Dec; 11(12):1354-9.
Score: 0.127
-
Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev. 2009 May; 229(1):126-44.
Score: 0.114
-
Emerging strategies in regulatory T-cell immunotherapies. Clin Adv Hematol Oncol. 2009 Jan; 7(1):1-10; quiz 11-2.
Score: 0.111
-
The expanding universe of regulatory T cell subsets in cancer. Immunity. 2007 Aug; 27(2):185-7.
Score: 0.101
-
On the TRAIL toward death receptor-based cancer therapeutics. J Clin Oncol. 2007 Apr 10; 25(11):1305-7.
Score: 0.099
-
Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006 Oct; 213:131-45.
Score: 0.095
-
Immune suppression in the tumor microenvironment. J Immunother. 2006 May-Jun; 29(3):233-40.
Score: 0.092
-
Metabolic mechanisms of tumor resistance to T cell effector function. Immunol Res. 2005; 31(2):107-18.
Score: 0.084
-
Update on vaccines for solid tumors. Clin Adv Hematol Oncol. 2004 Mar; 2(3):158-9.
Score: 0.079
-
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit. JCO Precis Oncol. 2022 11; 6:e2200454.
Score: 0.072
-
Integrating IL-12 into therapeutic cancer vaccines. Cancer Chemother Biol Response Modif. 2002; 20:343-9.
Score: 0.068
-
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
Score: 0.063
-
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. Eur J Cancer. 2020 03; 127:52-66.
Score: 0.060
-
The immune system as anti-tumor sentinel: molecular requirements for an anti-tumor immune response. Crit Rev Oncog. 1999; 10(3):247-60.
Score: 0.056
-
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.
Score: 0.053
-
Fast Forward - Neoadjuvant Cancer Immunotherapy. N Engl J Med. 2018 05 24; 378(21):2034-2035.
Score: 0.053
-
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science. 2018 03 23; 359(6382):1366-1370.
Score: 0.053
-
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
Score: 0.052
-
MYC - a thorn in the side of cancer immunity. Cell Res. 2016 06; 26(6):639-40.
Score: 0.046
-
Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA. J Immunol. 2016 Apr 01; 196(7):3191-8.
Score: 0.046
-
Cutting Edge: Engineering Active IKKß in T Cells Drives Tumor Rejection. J Immunol. 2016 Apr 01; 196(7):2933-8.
Score: 0.046
-
Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015 Jun 25; 6:7458.
Score: 0.044
-
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 2014 Nov 20; 41(5):843-52.
Score: 0.042
-
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012 Oct 03; 10:205.
Score: 0.036
-
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012 Sep 01; 18(17):4785-93.
Score: 0.036
-
Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. J Transl Med. 2012 May 28; 10:108.
Score: 0.035
-
The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012 Jan 03; 10:1.
Score: 0.034
-
Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011 Dec 14; 9:214.
Score: 0.034
-
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery. J Transl Med. 2011 Sep 19; 9:155.
Score: 0.034
-
Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer. J Transl Med. 2011 May 12; 9:60.
Score: 0.033
-
Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. J Immunother. 2007 Sep; 30(6):577-90.
Score: 0.025
-
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005 Apr; 54(4):307-14.
Score: 0.021
-
Negative regulation of T-cell function by PD-1. Crit Rev Immunol. 2004; 24(4):229-37.
Score: 0.020
-
Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines. J Leukoc Biol. 2003 Jul; 74(1):69-80.
Score: 0.019
-
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer. 2020 04; 8(1).
Score: 0.015